Synthetic peptides based on VDAC1 binding sites were used to inhibit Bcl2, Bcl-xL, and HKII, preventing their association with VDAC1 and thus inhibiting cancer cells’ ability to evade apoptosis [83]. The gene discussed is VDAC1; the disease is cancer.